Profile: Acadia Pharmaceuticals Inc. is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. We focus on developing product candidates including pimavanserin, which is in phase III development for the treatment of Parkinson disease. Our AC-262271 is a small molecule product candidate for the treatment of glaucoma. Our AGN XX/YY is a new class of small molecule product candidate that provides the potential for a significant breakthrough in the treatment of chronic pain.